Psilocybin vs Salvinorin A
A side-by-side research comparison of Psilocybin and Salvinorin A across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Psilocybin | Salvinorin A |
|---|---|---|
| Full name | Psilocybin (from psilocybin mushrooms) | Salvinorin A (Salvia divinorum) |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (FDA Breakthrough Therapy for depression) | Varies by region; research compound |
| Mechanism | Converted in the body to psilocin, which activates serotonin 5-HT2A receptors in the brain. This temporarily loosens rigid thinking patterns and increases connectivity between brain networks. | Activates kappa-opioid receptors (not serotonin receptors), which makes its effects unlike LSD or psilocybin. |
| Molecular weight | 284.25 g/mol | 432.46 g/mol |
| Half-life | ~2-3 hours (psilocin) | Very short |
| Bioavailability | Oral | Oral |
| Typical dose | 10-30 mg in clinical trials | Varies by individual and setting |
| Frequency | One to a few supervised sessions | Occasional |
| Route | Oral, in a supervised therapeutic setting | Smoked, vaporized or held in the mouth |
Psilocybin reported benefits
- Studied for treatment-resistant depression
- Eases anxiety in life-threatening illness
- Explored for alcohol and tobacco addiction
- Often produces durable improvements after few doses
Salvinorin A reported benefits
- Unique kappa-opioid mechanism
- Very short experience
- Long traditional Mazatec use
- Of interest for depression research
Related comparisons
Research and educational reference only. Not medical advice.